Hyperbaric oxygen therapy to treat lingering COVID-19 symptoms.

Background: SARs-Cov-2 infections can produce prolonged illness and significant disability. Patients recovering from COVID-19 can have persistent symptoms leading to long-term morbidity. Methods: Six patients with long-lasting (> 30 days) COVID-19 symptoms were treated with hyperbaric oxygen (HBO2) therapy. All patients were assessed for symptoms using the ImPACT questionnaire, a muscle and joint pain scale, and a modified Borg dyspnea scale. Patients were assessed before, during and after HBO2 treatments. Results: All patients saw improvements in the measured symptoms to levels that were the same as pre-infection levels (five of six patients) or had significant improvement in symptoms (one patient). Conclusion: The results suggest that HBO2 helped to improve symptom scores, reduce the length of time of symptoms, and improved the quality of life. More detailed and randomized studies are needed to confirm the results in this report.

Clinical results in brain injury trials using HBO2 therapy: Another perspective.

The current debate surrounding the use of hyperbaric oxygen (HBO2) for neurological indications, specifically mild to moderate chronic traumatic brain injury (mTBI) and post-concussion syndrome (PCS), is mired in confusion due to the use of non-validated controls and an unfamiliarity by many practitioners of HBO2 therapy with the experimental literature. In the past 40 years, the use of an air sham (21% oxygen, 1.14-1.5 atmospheres absolute/atm abs) in clinical and animal studies, instead of observational or crossover controls, has led to false acceptance of the null hypothesis (declaring no effect when one is present), due to the biological activity of these "sham" controls. The recent Department of Defense/Veterans Administration (DoD/VA) sponsored trials, previous published reports on the use of HBO2 therapy on stroke and mTBI and preliminary reports from the HOPPS Army trial, have helped to highlight the biological activity of pressurized air, validate the development of a convincing control for future studies and demonstrate the effectiveness of a hyperbaric intervention for mTBI/ PCS. Approval of HBO2 for neurological indications, especially for mTBI/PCS, should be granted at the federal, state and certifying body levels as a safe and viable treatment for recovery in the post-acute phase.

The 16-year evolution of a military-civilian partnership: The University of Alabama at Birmingham experience.

BACKGROUND: At the University of Alabama at Birmingham (UAB), a multi-tiered military-civilian partnership (MCP) has evolved since 2006. We aimed to outline this model to facilitate potential replication nationally. METHODS: We performed a comprehensive review of the partnership between UAB, the United States Air Force Special Operations Command, and the Department of Defense (DoD) reviewing key documents and conducting interviews with providers. As a purely descriptive study, this project did not involve any patient data acquisition or analysis and therefore was exempt from institutional review board approval per institutional policy. RESULTS: At the time of this review, six core programs existed targeting training, clinical proficiency, and research. Training: (1) The Special Operations Center for Medical Integration and Development trains up to 144 combat medics yearly. (2) UAB trains one integrated military Surgery resident yearly with two additional civilian-sponsored military residents in Emergency Medicine. (3) UAB's Surgical Critical Care Fellowship had one National Guard member with two incoming Active-Duty, one Reservist and one prior service member in August 2022. Clinical Proficiency: (4) UAB hosts four permanently assigned United States Air Force Special Operations Command Special Operations Surgical Teams composed of general surgeons, anesthesiologists, certified registered nurse anesthetists, surgical technologists, emergency physicians, critical care registered nurses, and respiratory therapists totaling 24 permanently assigned active-duty health care professionals. (5) In addition, two fellowship-trained Air Force Trauma Critical Care Surgeons, one Active-Duty and one Reservist, are permanently assigned to UAB. These clinicians participate fully and independently in the routine care of patients alongside their civilian counterparts. Research: (6) UAB's Division of Trauma and Acute Care Surgery is currently conducting nine DoD-funded research projects totaling $6,482,790, and four research projects with military relevance funded by other agencies totaling $15,357,191. CONCLUSION: The collaboration between UAB and various elements within the DoD illustrates a comprehensive approach to MCP. Replicating appropriate components of this model nationally may aid in the development of a truly integrated trauma system best prepared for the challenges of the future. LEVEL OF EVIDENCE: Economic and Value-based Evaluations; Level IV.

Predicting success in the tactical air combat party training pipeline.

OBJECTIVES: To develop a statistical model that predicts the likelihood of success or failure of military training candidates using tests administered before initial skill training as inputs. METHODS: Data were acquired from candidates before the start of U.S. Air Force Tactical Air Control Party training, including (1) demographic, (2) psychological composition evaluated using Emotional Quotient Inventory, (3) physical performance capability, (4) a physical activity questionnaire, and (5) salivary fatigue biomarker index. A total of 126 candidates were tracked until they either passed or failed the training, and a total of 55 variables were used as inputs for creation of the model. RESULTS: Clustering analysis of the data revealed that only 4 of 55 variables were useful for predicting success or failure. The variables in the order of their importance are as follows: run time, number of miles run per week in the last year, level of salivary fatigue biomarker, and height. CONCLUSIONS: The results suggest that simple testing methods can identify candidates at high risk of failure.

Evaluation of intraosseous delivery of factor VIIa during hemorraghic shock in the pig.

The purpose of this investigation is to determine if intraosseous infusion (IO) is a suitable method for the delivery of recombinant human factor VIIa (rFVIIa) during hemorrhagic shock. The measures that were used to evaluate IO delivery suitability included: (1) determination of clinically significant local or systemic toxicity and (2) demonstration that systemic blood levels of rFVIIa increased rapidly following administration. Our results indicate that there was no evidence of significant local or systemic toxicity following infusion and that the systemic blood concentration of rFVIIa peaks immediately after the end of infusion. This result suggests that the systemic blood level profiles of rFVIIa delivered by IO infusion are similar to those that could be produced by intravenous (IV) administration. Furthermore, in all 25 test animals, access to the systemic circulation during shock was achieved as evidenced by rapid increase in a marker dye (flourescein) or rFVIIa in the blood. We conclude that administration of rFVIIa via IO infusion is a reasonable safe method and is likely to produce blood levels required for improved hemostasis during shock.

Case report: Treatment of mild traumatic brain injury with hyperbaric oxygen.

Two United States Air Force Airmen were injured in a roadside improvised explosive device (IED) blast in Iraq in January 2008. Both airmen suffered concussive injuries and developed irritability, sleep disturbances, headaches, memory difficulties and cognitive difficulties as symptoms of mild traumatic brain injury (mTBI). Six months after injury, repeat Automated Neuropsychological Assessment Metrics (ANAM) testing showed deterioration, when compared to pre-injury baseline ANAM assessment, in all measured areas (simple reaction time, procedural reaction time, code substitution learning, code substitution delayed, mathematical processing, and matching to sample). The airmen were treated with hyperbaric oxygen in treatments of 100% oxygen for one hour at 1.5 atmospheres absolute, resulting in rapid improvement of headaches and sleep disturbances, improvement in all symptoms and resolution of most symptoms. Repeat ANAM testing after completion of the hyperbaric treatments - nine months after initial injury - showed improvement in all areas, with most measures improving to pre-injury baseline levels. The airmen received no other treatment besides medical monitoring. Repeat neuropsychologic testing confirmed the improvement. We conclude that the improvement in symptoms and ANAM performance is most likely attributable to HBO treatment.

Hyperbaric oxygen: B-level evidence in mild traumatic brain injury clinical trials.

OBJECTIVE: First, to demonstrate that B-level evidence exists for the use of hyperbaric oxygen therapy (HBOT) as an effective treatment in mild to moderate traumatic brain injury/persistent postconcussion syndrome (mTBI/PPCS). Second, to alert readers and researchers that currently used pressurized air controls (≥21% O2, >1.0 ATA) are therapeutically active and cannot be utilized as sham controls without further validation. METHOD: Review of published, peer-reviewed articles of HBOT prospective and controlled clinical trials of mTBI/PPCS symptoms. RESULTS: Published results demonstrate that HBOT is effective in the treatment of mTBI/PPCS symptoms. Doses of oxygen that are applied at ≥21% O2 and at pressures of >1.0 ATA produce improvements from baseline measures. Some of the recently published clinical trials are mischaracterized as sham-controlled clinical trials (i.e., sham = 21% O2/1.2-1.3 ATA), but are best characterized as dose-varying (variation in oxygen concentration, pressure applied, or both) clinical trials. CONCLUSIONS: Hyperbaric oxygen and hyperbaric air have demonstrated therapeutic effects on mTBI/PPCS symptoms and can alleviate posttraumatic stress disorder symptoms secondary to a brain injury in 5 out of 5 peer-reviewed clinical trials. The current use of pressurized air (1.2-1.3 ATA) as a placebo or sham in clinical trials biases the results due to biological activity that favors healing.

OK, Doc . . . What Do I Really Have? Posttraumatic Stress Disorder Versus Traumatic Brain Injury.

The authors review the diagnostic overlap that exists between posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI). Achieving the correct diagnosis is much more difficult and the potential to inappropriately treat patients is greater than most physicians realize. The need to properly diagnose and select appropriate treatment strategies is essential, especially with TBI cases. A number of new and experimental therapies are being used to treat PTSD effectively and reverse the neurological sequelae of TBI, potentially returning to active duty Servicemembers who are undergoing a medical review board.

Facilitation of recovery from acute blood loss with hyperbaric oxygen.

BACKGROUND: Hyperbaric oxygen (HBO) has been used for more than 25 years as therapy for extreme blood loss in cases where transfusion has been unavailable. The use of HBO for lesser amounts of blood loss to avoid the transfusion of blood products has not been investigated. HYPOTHESIS: Hyperbaric oxygen up-regulates hemoglobin synthesis after acute blood loss in an animal model of moderate (30%) blood loss. DESIGN: Twenty-four New Zealand white rabbits were bled to a calculated loss of 30% of the circulating blood volume. The rabbits received Ringer lactate infusions to correct hypovolemia and were divided into 2 groups: a control group and a treatment group receiving HBO. INTERVENTION: One group of 12 animals received no treatment other than Ringer lactate resuscitation, whereas the other group of 12 received 5 HBO treatments in the 4 days immediately following blood loss. Hemoglobin levels and reticulocyte counts were monitored for 14 days after the bleeding episode. RESULTS: The control group was more affected by the blood withdrawal than the HBO group, reaching a low of 37% hemoglobin loss compared with 29% hemoglobin loss at 48 hours (P<.001). The HBO group recovered faster, reaching the baseline level of hemoglobin in 11 days as opposed to 14 days for the control group (P<.001). Reticulocyte counts were not significantly affected by HBO treatment. CONCLUSIONS: Treatment with HBO favorably affected recovery from moderate (30%) acute blood loss, resulting in lessened effects at 48 hours and hastening recovery to baseline hemoglobin levels. Our results support the data gained from clinical experience treating extreme blood loss with HBO.

Case history of serious altitude decompression sickness following rapid rate of ascent.

Neurologic and respiratory decompression sickness (DCS) symptoms occurring in the same individual represent complications rarely observed in altitude research. A case is presented of multi-symptom serious DCS resulting from exposure to 12,192 m (40,000 ft). Following 90 min of preoxygenation, the patient was decompressed in a hypobaric chamber from ground level to 12,192 m in 30 s. After 69 min at altitude he developed substernal chest pressure and the flight was immediately terminated. During the chamber descent the patient appeared disoriented. By 5486 m (18,000 ft) his chest pressure had resolved. The post-flight medical exam revealed multiple neurological abnormalities. He underwent a Table VI hyperbaric oxygen treatment with complete resolution of all abnormal neurological findings.

A retrospective evaluation of digital wound imaging to predict response to hyperbaric oxygen treatment.

As new wound care treatments become available, correct initial treatment selection and dynamic modification of regimens, based on wound response to treatment, must be applied to improve outcomes and reduce cost. One alternative is wound morphometry using digital wound images to evaluate wound response to treatment in realtime. To determine whether wound area measurements taken during the first 3 weeks of hyperbaric oxygen treatment predict eventual treatment response and how demographic and disease factors impact hyperbaric oxygen treatment response, a retrospective study using digital wound images, demographic data, and available clinical laboratory values was conducted. Participants included 29 wound care patients with nonhealing wounds of the lower extremities receiving treatment at a hyperbaric wound care facility. Conventional wound care (ie, debridement, dressing changes, and topical agents) plus hyperbaric oxygen treatment (100% oxygen breathing at 2.4 atmospheres absolute for 90 minutes) given once every weekday for up to 20 weeks was provided. Graphical analysis of normalized wound area over time revealed two groups: minimal responders (n=13) and robust responders (n=16). Minimal response was characterized by delayed onset of wound area reduction and virtual cessation of reduction by week 3. Robust response was continuous, sustained, and resulted in average wound area reduction of 80% by end of treatment, compared to 47% in minimally responsive patients. Age, blood glucose, and serum creatinine significantly affected the wound healing response to hyperbaric oxygen treatment (P<0.05). Digital images obtained during the first 3 weeks of treatment predicted if a patient is minimally responsive to hyperbaric oxygen treatment with 100% accuracy. Area measurements obtained in this manner can be used to identify patients minimally responsive to hyperbaric oxygen treatment, enabling rapid assessment of treatment response to make timely changes in therapy in order to optimize treatment outcomes.

Thermal injury resulting from application of a granular mineral hemostatic agent.

BACKGROUND: Uncontrolled hemorrhage accounts for the majority of deaths in combat. Effective topical hemostatic agents suitable for use on the battlefield may be valuable in controlling hemorrhage until definitive surgical intervention is possible. In an effort to identify a hemostatic agent suitable for battlefield use, we evaluated several potential hemostatic agents in a swine injury model and noted thermal injury to tissues with a granular mineral hemostatic agent (QuikClot). METHODS: Anesthetized swine were maintained with a mean arterial pressure in excess of 60 mm Hg. Cutaneous, muscular, hepatic, splenic, venous, and arterial wounds were created in a standardized fashion. Topical hemostatic agents were immediately applied to the wounds and the amount of bleeding and time to hemostasis were noted. RESULTS: The results reported here are part of a larger study in which a variety of hemostatic agents were evaluated. Only the findings related to the granular mineral hemostatic agent are discussed here. Application of the agent resulted in elevated tissue surface temperatures in excess of 95 degrees C and internal tissue temperatures exceeding 50 degrees C, 3 mm deep to the bleeding surface. Necrosis of fat and muscle were noted as well as full and partial thickness cutaneous burns. CONCLUSIONS: Topical administration of a granular mineral hemostatic agent to a variety of wounds in an experimental swine model resulted in thermal tissue injury and necrosis. Suggestions for reducing the extent of injury with this product are offered.